Volatility & Risk
Unilife Corp (NASDAQ: UNIS) and Strata Skin Sciences (NASDAQ:SSKN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitabiliy, earnings, analyst recommendations, dividends, risk, institutional ownership and valuation.
Unilife Corp has a beta of -0.92, indicating that its stock price is 192% less volatile than the S&P 500. Comparatively, Strata Skin Sciences has a beta of 0.48, indicating that its stock price is 52% less volatile than the S&P 500.
Institutional & Insider Ownership
14.9% of Unilife Corp shares are held by institutional investors. Comparatively, 94.3% of Strata Skin Sciences shares are held by institutional investors. 1.9% of Unilife Corp shares are held by insiders. Comparatively, 12.9% of Strata Skin Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares Unilife Corp and Strata Skin Sciences’ gross revenue, earnings per share (EPS) and valuation.
Strata Skin Sciences has higher revenue and earnings than Unilife Corp.
This table compares Unilife Corp and Strata Skin Sciences’ net margins, return on equity and return on assets.
This is a breakdown of current recommendations and price targets for Unilife Corp and Strata Skin Sciences, as provided by MarketBeat.com.
Strata Skin Sciences has a consensus price target of $12.00, suggesting a potential upside of 552.17%. Given Strata Skin Sciences’ higher probable upside, analysts clearly believe Strata Skin Sciences is more favorable than Unilife Corp.
Strata Skin Sciences beats Unilife Corp on 8 of the 9 factors compared between the two stocks.
Unilife Corp Company Profile
Unilife Corp is engaged in the designing, development and manufacturing of injectable drug delivery systems. The Company has a portfolio of product platforms, including pre-filled syringes, disposable and reusable auto-injectors, drug reconstitution delivery systems, ocular delivery systems, and other systems for the targeted delivery of injectable therapies. The majority of its products are designed for sale directly to pharmaceutical and biotechnology companies supplying them as drug-device combination products, pre-filled and ready for administration by end-users, such as health-care providers or patients. Its other products, such as reusable auto-injectors and certain systems for targeted drug delivery are designed either to be sold to pharmaceutical or biotechnology companies for use as combination products or to be sold directly to a health care provider or end user without having the device pre-filled by a pharmaceutical company.
Strata Skin Sciences Company Profile
STRATA Skin Sciences, Inc., formerly MELA Sciences, Inc., is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging. The XTRAC and VTRAC products are the devices used for the treatment of psoriasis, vitiligo and other skin disorders. The XTRAC system delivers targeted ultraviolet light to affected areas of skin, leading to psoriasis clearing and vitiligo repigmentation, following a series of treatments. The Company’s technology includes XTRAC Excimer Laser, VTRAC Lamp and MelaFind. MelaFind is a non-invasive, point-of-care instrument to aid dermatologists in their decision to biopsy suspicious pigmented lesions, such as melanoma. The Company has approximately two distribution channels for phototherapy treatment equipment.